Historical Press Releases

2015

Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome

Princeton, NJ – January 5, 2015 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine

Princeton, NJ – January 29, 2015 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Princeton, NJ – February 2, 2015 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City

Princeton, NJ – February 5, 2015 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical...

FDA Grants Soligenix “Fast Track” Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma

Princeton, NJ – January 7, 2015 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Show per page